BlueMountain Capital Management LLC trimmed its holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 35.3% in the second quarter, HoldingsChannel reports. The institutional investor owned 35,250 shares of the biopharmaceutical company’s stock after selling 19,196 shares during the quarter. BlueMountain Capital Management LLC’s holdings in Sangamo Therapeutics were worth $501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of the stock. Leisure Capital Management grew its holdings in Sangamo Therapeutics by 9.3% in the 2nd quarter. Leisure Capital Management now owns 43,676 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 3,714 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Sangamo Therapeutics by 7.7% during the 1st quarter. Principal Financial Group Inc. now owns 54,480 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 3,910 shares in the last quarter. Amalgamated Bank boosted its stake in Sangamo Therapeutics by 38.4% during the 2nd quarter. Amalgamated Bank now owns 15,478 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 4,294 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in Sangamo Therapeutics by 42.5% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 17,446 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 5,200 shares in the last quarter. Finally, Riverhead Capital Management LLC boosted its stake in Sangamo Therapeutics by 218.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,667 shares in the last quarter. 63.84% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have issued reports on the company. BidaskClub raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 20th. Cowen reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research note on Monday, July 23rd. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Bank of America assumed coverage on Sangamo Therapeutics in a research note on Wednesday, June 20th. They set a “buy” rating and a $24.00 price target for the company. Finally, Wedbush reaffirmed a “hold” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, August 9th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $21.00.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $21.42 million for the quarter, compared to the consensus estimate of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business’s revenue for the quarter was up 159.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.17) earnings per share. equities research analysts forecast that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current year.
In other news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $14.77, for a total transaction of $73,850.00. Following the completion of the sale, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at approximately $180,932.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director H Stewart Parker acquired 2,000 shares of Sangamo Therapeutics stock in a transaction dated Friday, September 7th. The shares were bought at an average cost of $13.52 per share, with a total value of $27,040.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 30,000 shares of company stock valued at $441,200. Corporate insiders own 1.20% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Featured Story: Understanding Average Daily Trade Volume
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.